David Kaslow

From SourceWatch
Jump to navigation Jump to search

"David Kaslow is MD, Vice President for Essential Medicines at Path, which includes Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). As the director of CVIA, he leads the development and introduction of lifesaving vaccines for the most vulnerable children and communities around the world.

"Dr. Kaslow has more than 25 years of experience in vaccine research and development. Before joining PATH in 2012 as director of MVI's work to drive the development of safe and effective vaccines against malaria, he held key advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines. Prior to that, he oversaw project leadership and management of Merck Research Laboratories’ vaccine pipeline and founded the Malaria Vaccine Development Unit at the National Institutes of Health.

"As a basic research scientist, Dr. Kaslow completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He also has directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, Dr. Kaslow has contributed to the vaccine application of tools originally developed for gene therapy. He holds or coholds more than a dozen patents and has published more than 150 scientific papers." [1]

"Kaslow is a physician-scientist with 25 years of vaccine research and development experience whose professional career encompasses the academic, governmental, and private sectors. He served as vice president and head of vaccine project leadership and management at Merck Research Laboratories and worked for more than a decade as a tenured scientist at the National Institutes of Health, where he founded the Malaria Vaccine Development Unit. He became director of MVI in early 2012 and, prior to that, served for three years as chair of MVI’s Vaccine Science Portfolio Advisory Council." [1]

Resources and articles

Related Sourcewatch


  1. Strategic Advisory Committee, Hilleman Laboratories, accessed April 23, 2020.